SLC34A2-ROS1 fusion (~10% of ROS1+ NSCLC) responds to standard ROS1-TKI therapy identical...
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BMA-ROS1-SLC34A2-NSCLC |
|---|---|
| Type | Actionability |
| Status | reviewed 2026-04-27 | pending_clinical_signoff | actionability review required |
| Diseases | DIS-NSCLC |
| Sources | SRC-CIVIC SRC-ESMO-NSCLC-METASTATIC-2024 SRC-NCCN-NSCLC-2025 |
Actionability Facts
| Biomarker | BIO-ROS1-FUSION |
|---|---|
| Variant | SLC34A2-ROS1 fusion |
| Disease | DIS-NSCLC |
| ESCAT tier | IA |
| Recommended combinations | repotrectinib monotherapy, entrectinib monotherapy, crizotinib monotherapy |
| Evidence summary | SLC34A2-ROS1 fusion (~10% of ROS1+ NSCLC) responds to standard ROS1-TKI therapy identically to other partners. No partner-specific treatment differentiation in current guidelines. |
Notes
ESCAT IA. Partner identification is informative but not therapy-altering.
Used By
No reverse references found in the YAML corpus.